KALA - カラ・ファ―マシュ―ティカルズ (Kala Pharmaceuticals Inc.) カラ・ファ―マシュ―ティカルズ

 KALAのチャート


 KALAの企業情報

symbol KALA
会社名 Kala Pharmaceuticals Inc (カラ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カラ・ファーマスーティカルズ(Kala Pharmaceuticals Inc.)はナノ粒子ベースの粘膜浸透性粒子(MPP)技術による治療薬の開発と商品化に重点を置くバイオ医薬品会社である。同社の最初の焦点は眼疾患の治療にある。同社の製品候補には、KPI-121 1%、KPI-121 0.25%およびMPP rTKIプログラムが含まれる。同社はKPI-121 1%について2つの第III相臨床試験を完了する。KPI-121 0.25%はドライアイ疾患の徴候および症状の一時的軽減用製品候補である。KPI-121 1%は手術後の炎症および疼痛処置用の1日2回の製品候補である。MPP rTKIプログラムは毎月の間隔で患者の眼に直接注入する網膜疾患治療法である。   カラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。眼科疾患を治療するナノ粒子ベ―ス「Mucus Penetraiting Particles」(MPP)技術を用いた医薬品の開発・商業化に従事する。ナノ粒子はサイズが選択可能で、粘液による薬物粒子の移動性を高める。眼科手術後の炎症、ドライアイや網膜疾患の治療に使われる。本社はマサチュ―セッツ州ウォルサム。   Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
本社所在地 100 Beaver Street Suite 201 Waltham MA 02453 USA
代表者氏名 Mark T. Iwicki Mark T. Iwicki
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 781-996-5252
設立年月日 39965
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 37人
url www.kalarx.com
nasdaq_url https://www.nasdaq.com/symbol/kala
adr_tso
EBITDA EBITDA(百万ドル) -45.82500
終値(lastsale) 8.31
時価総額(marketcap) 204481460.94
時価総額 時価総額(百万ドル) 306.72840
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 235.29040
当期純利益 当期純利益(百万ドル) -47.38200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kala Pharmaceuticals Inc revenues was not reported. Net loss increased 25% to $25.9M. Higher net loss reflects General and administrative - Balancing v increase from $2.4M to $9.9M (expense) Stock-Based Compensation increase from $697K to $2.8M (expense) Stock-Based Compensation increase from $392K to $1.4M (expense).

 KALAのテクニカル分析


 KALAのニュース

   Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know  2020/05/05 16:00:05 Zacks Investment Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?  2020/05/01 15:30:17 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)  2020/04/16 16:00:05 Zacks Investment Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Kala pharmaceuticals up 16% premarket after pricing stock offering  2020/03/11 10:47:28 Seeking Alpha
Kala Pharmaceuticals (NASDAQ:KALA) has priced its public offering of 16M common shares at $7.89 per share, for gross proceeds of ~$126.2M. Underwriters' ov
   Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?  2020/03/10 15:30:09 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know  2020/05/05 16:00:05 Zacks Investment Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?  2020/05/01 15:30:17 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)  2020/04/16 16:00:05 Zacks Investment Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Kala pharmaceuticals up 16% premarket after pricing stock offering  2020/03/11 10:47:28 Seeking Alpha
Kala Pharmaceuticals (NASDAQ:KALA) has priced its public offering of 16M common shares at $7.89 per share, for gross proceeds of ~$126.2M. Underwriters' ov
   Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?  2020/03/10 15:30:09 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?  2020/05/01 15:30:17 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)  2020/04/16 16:00:05 Zacks Investment Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Kala pharmaceuticals up 16% premarket after pricing stock offering  2020/03/11 10:47:28 Seeking Alpha
Kala Pharmaceuticals (NASDAQ:KALA) has priced its public offering of 16M common shares at $7.89 per share, for gross proceeds of ~$126.2M. Underwriters' ov
   Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?  2020/03/10 15:30:09 Zacks Investment Research
Is (KALA) Outperforming Other Medical Stocks This Year?
   Stock To Watch: Here's Why You Need To Keep An Eye On Kala Pharma (KALA)  2020/03/04 10:55:00 RTT News
Shares of Kala Pharmaceuticals Inc. (KALA) have gained over 10 percent in the last 5 trading days as the Company gears up to report results from STRIDE 3 - a phase III clinical trial for EYSUVIS, its product candidate for the short-term treatment of dry eye disease, this month.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラ・ファ―マシュ―ティカルズ KALA Kala Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)